GLOBAL CANNABIS APP Forum: Community User: Rondello

Wohl eher Tiefflug, denn wer braucht die Software schon ? Sind grad die neuen Zahlen per 31.3.2019 rausgekommen, sieht immer noch sehr mau aus: Cash= 22,600 C$ , plus gebundene Receivables, die ich für fragwürdig halte, Ausgaben im lezten Quartal = 530,000 C$; https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00036309

Bin bereit für den ersten Höhenflug 🚀

https://youtu.be/vDnErEZvdbQ

https://youtu.be/CcWetSFkcYs

https://finance.yahoo.com/news/uptick-newswire-hosts-global-cannabis-120000759.html?guccounter=1&guce_referrer=aHR0cHM6Ly90LmNvL0VPbkhkMjFjUjI_YW1wPTE&guce_referrer_sig=AQAAAFAZwZmxcA-mtaMerXLwY_6yH3Jsju53aOJI7JDAQWV-AKx28OS8o-ZSoU1EUUBm2zXobBI6-tEPSEN8LTFiJhn0Yo7LfMVwCBC9m8d4h1GYyZ1Rgt7qYNCVB3LBfGYtvd5ePpmjgwC5WQyw01BTuYR1bUOYhGMJw8WIsJQutPzP

http://cannappscorp.com/2019/05/15/brad-moores-interview-for-uptick-news-wire-may-13th-2019/

Auszug (per Übersetzer): Im Rahmen der Lizenzvereinbarung hat Sequoya das ausschließliche Recht, die Citizen Green Prescriptii-Patientenversorgungslösung von GCAC an über 13.700 Apotheken in Polen zu vermarkten. Sequoya wird ausschliesslich: i) GCAC 5.000.000 Stammaktien von Sequoya ausgeben; ii) GCAC 100.000 USD per Wandelschuldverschreibung zu zahlen; und iii) GCAC eine monatliche Gebühr zahlen, die auf der Anzahl der Benutzer basiert. Die Laufzeit der Lizenzvereinbarung beträgt ein Jahr mit automatischer Verlängerung. GCAC wird im Austausch für 4.000.000 GCAC-Aktien zusätzlich 5.000.000 Sequoya-Aktien erwerben. Sequoya gewährt GCAC eine Option (die „Option“) zum Kauf von 10.000.000 Sequoya-Aktien für 600.000 USD für eine Laufzeit von 90 Tagen ab Abschluss des Lizenzvertrags. Vorbehaltlich der behördlichen Genehmigung wird GCAC 10.000.000 Aktien von Sequoya besitzen und eine Option zum Kauf weiterer 10.000.000 Aktien haben. Sequoya hat jetzt ungefähr 70.310.000 ausgegeben, so dass GCAC ungefähr 12,5% von Sequoya und 22% besitzt, wenn es die Option ausübt.

Gerne - Ich bin „startklar“ 😉

Danke Ray Kommt eine Rally ?

http://cannappscorp.com/2019/05/13/global-cannabis-executes-first-stage-of-vertical-integration-strategy-for-eu-and-israeli-medical-cannabis-markets/

Die Aktie lebt ja noch

https://youtu.be/YiUeTzV8Mk4 Neu in Polnisch

Wieder gute Nachrichten ! Jedoch brauchen wir endlich Umsatz und den erheblich ... .

GCAC CEO Update - March 2019 Over the past number of years, we have witnessed a change of attitude towards hemp and cannabis across many global regions. Evidence of this change include the recent 2018 Farm Bill passed by the US Congress in December 2018, the EU Cannabis Resolution passed in February 2019 and the World Health Organization (WHO) recently recommending rescheduling cannabis under international drug treaties. These and other market actions are predicated on the keen desire to create a greater understanding of the medicinal uses of cannabis, specifically CBD. To achieve this greater understanding much more information and data on the effects of prescribing medical cannabis is required. Global Cannabis Applications Corp. is currently developing a medical cannabis database through its multilayered technology that drives data interactions from interconnected customers, retailers and product producers. GCAC is using this database to create better outcomes for medical cannabis patients and our underlying technology can be used to meet the EU GMP requirements. In *** with actions of the US Congress, EU and WHO, the Israeli parliament recently voted to permit the export of medical cannabis, clearing the way for Israel to compete in the fast-growing global medical cannabis marketplace. With an abundance of natural sunlight, Israeli growers will be able to produce medical-grade cannabis at a cost per gram well below current North American producers. In addition, Israel’s proximity to Europe will provide for a cost-effective and reliable inventory for the EU markets. However, local growers will have to be EU GMP certified and will have to ensure tracking of all aspects of the supply chain from planting through to retail sales. Much of this is accomplished with GCAC’s Citizen Green brand technology, Prescriptii Patient Care and Seed2Seed solutions. Therefore, we have identified an opportunity for GCAC to become a fully integrated medical cannabis company. By working with Israeli based licensed producers to become EU GMP compliant and tracking each product through to European medical cannabis retailers, GCAC’s Citizen Green will become recognized as a truly global brand. Our integrated approach is not limited only to Israel and Europe but can apply to the many emerging markets including Latin America, Asia and many soon to be legal med-canna US states. The economic rewards are significant as EU wholesale prices per gram of medical cannabis average up to €7.5 per gram (CDN$11.50). The recent success of Village Farms (TSX: VFF) provides an excellent example of the success of a comparable company with a low cost of production and capacity in the market. (note: VFF is projected to be providing cannabis to the recreational market in North America at a wholesale of CDN$5 per gram). For your review, we have created a two-page overview, found here. If you have any questions about GCAC’s vision, please do not hesitate to contact us at info@cannappscorp.com or if you are interested in finding out about investment opportunities please do not hesitate to contact Mr. Ward Kondas at wkondas@gmail.com.

Die Akzie ist Schrott hir passiert ja gar nicht's mehr........

Morgen Gibt es neue news weil Hir tut sich garnichts mehr.......